• Optimized hGBA1 mRNA for Gaucher Disease Therapy

  2026-09-17

  The reference study engineered human GBA1 mRNA through untranslated-region, codon, and poly(A)-tail optimization to increase glucocerebrosidase expression and durability. Its cellular and mouse experiments support mRNA–lipid nanoparticle delivery as a preclinical strategy for restoring lysosomal enzyme function, while also identifying the assay and biodistribution questions that remain before translation.

• Anlotinib hydrochloride in Angiogenesis Assays

  2026-09-17

  Anlotinib hydrochloride combines nanomolar activity across VEGFR2, PDGFRβ, and FGFR1 with measurable effects in migration, tube-formation, and ERK readouts. This article turns that profile into a concentration-resolved workflow for mechanism-led angiogenesis studies and translational cancer research.

• Caveolin-1, Cholesterol, and MASLD Progression

  2026-09-17

  The reference study identifies Caveolin-1 (CAV1) as a regulator of hepatic cholesterol homeostasis that limits endoplasmic reticulum stress and pyroptosis during metabolic dysfunction-associated steatotic liver disease. By combining CAV1-deficient mice, transcriptomics, human liver samples, and in vitro experiments, it connects altered cholesterol transport through FXR/NR1H4 and ABCG5/ABCG8 with disease progression and suggests practical avenues for integrated biochemical and membrane-imaging studies.

• Anlotinib Hydrochloride for Angiogenesis Assays

  2026-09-16

  Build mechanism-led angiogenesis experiments around receptor phosphorylation, endothelial phenotypes, and ERK pathway readouts. This guide connects practical migration and tube-formation workflows with translational evidence from a rare tumor case report while emphasizing assay controls and troubleshooting.

• Separating Growth Inhibition from Cell Killing in Cancer

  2026-09-15

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these measures capture different components of anticancer drug response. Its central implication is practical: cancer research assays should evaluate growth inhibition, cell death, and their timing as related but noninterchangeable outcomes.

• Fluoxetine HCl: Translational Research Workflows

  2026-09-15

  Fluoxetine HCl supports both defined serotonergic receptor assays and translational models of motivation, allowing researchers to separate acute signaling effects from persistent developmental phenotypes. This guide connects solvent preparation, 5-HT2C workflows, and progressive-ratio behavior with practical troubleshooting and assay-selection strategies.

• Apicidin: Selective HDAC Inhibition and Research Use

  2026-09-14

  Apicidin is a fungal histone deacetylase inhibitor with a product-reported biochemical preference for HDAC3 over HDAC6. Evidence supports its use as an anti-proliferative and epigenetic research tool, while recent oocyte findings define important reproductive-toxicity limits.

• Protease Inhibitor Cocktail: EDTA-Free Lab Guide

  2026-09-14

  Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) helps limit proteolytic degradation during protein extraction and downstream analysis. It is suited to Western blotting, co-immunoprecipitation, pull-down, phosphorylation, and kinase workflows, but is not a substitute for EDTA when metal-ion chelation is required or when DMSO is incompatible.

• 2X Taq PCR Master Mix for Plant Virus Workflows

  2026-09-13

  Build a practical molecular confirmation workflow around a dye-integrated reagent for genotyping, cloning, and plant-virus testing. This guide connects field-image screening with PCR-based follow-up while showing where direct gel loading, TA cloning, and careful optimization add value.

• Vancomycin at the Microbiota–Immunity Interface

  2026-09-12

  Explore how Vancomycin can function beyond a conventional glycopeptide antibiotic in experiments linking bacterial cell wall disruption to microbiota and immune phenotypes. This article translates a Lactobacillus–UDCA ulcerative colitis study into a rigorous framework for designing and interpreting antibiotic perturbation assays.

• Separating Growth Arrest from Cell Death In Vitro

  2026-09-12

  Hannah Schwartz’s dissertation shows that relative viability and fractional viability capture different components of anticancer drug response. By considering proliferative arrest, cell killing, and response timing as related but distinct measurements, the work provides a more interpretable framework for in vitro oncology experiments.

• Recombinant Mouse IFN-γ in MASH-HCC Assays

  2026-09-11

  Recombinant Mouse IFN-γ provides a defined, activity-validated stimulus for testing whether metabolically stressed tumor cells can recover MHC-I antigen presentation. This guide converts the bile acid–NLRC5 findings in MASH-HCC into practical dose-response, co-culture, macrophage, and T-cell workflows.

• KR-12: Applied Workflows for Antimicrobial Research

  2026-09-11

  KR-12 converts a minimal LL-37 fragment into a practical tool for membrane, biofilm, LPS, and host-response assays. This workflow-focused guide explains how to prepare the TFA salt, select informative endpoints, compare planktonic and biofilm activity, and troubleshoot concentration, matrix, and cytotoxicity effects.

• ATP Strategy for PXDN-Driven Glioblastoma Research

  2026-09-10

  A mechanistic and translational framework for using ATP abundance to strengthen PXDN–LDHA studies in glioblastoma, with practical guidance for cellular ATP quantification, tissue workflows, and causal metabolic validation.

• D-N-Acetylgalactosamine: Workflow and QC Guide

  2026-09-10

  D-N-Acetylgalactosamine (SKU B7904) provides a high-purity, water- and DMSO-soluble reagent for controlled analysis of glycoprotein constituents and glycosylation-related workflows. It is not appropriate for ethanol-based preparation or long-term storage of working solutions, and the guidance below is dossier-based because no directly matched paper evidence was supplied.

8450 records 1/564 page Next 12345 下5页 Last page